Stock Events

Stock Events

Turnstone Biologics 

$0.36
3
+$0.01+1.43% Friday 20:00

Statistics

Day High
0.36
Day Low
0.36
52W High
0.78
52W Low
0.29
Volume
283,774
Avg. Volume
454,383
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

7NovExpected
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
-0.92
-0.61
-0.31
0
Expected EPS
-0.14
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
0Revenue
-70.84MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TSBX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech develops individualized cancer therapies using mRNA, a method that competes with Turnstone's viral vector-based cancer vaccines.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, specializes in CAR-T therapies for oncology, competing in the broader cancer treatment landscape.
Moderna
MRNA
Mkt Cap10.61B
Moderna, known for mRNA technology, is expanding into oncology treatments, potentially overlapping with Turnstone's immunotherapy approaches.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing for cancer treatments, which could compete with Turnstone's gene therapy strategies.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics works on allogeneic CAR-T therapies for cancer, a direct competitor in the cell therapy space for oncology.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics engages in genomic medicine, including gene therapy, competing with Turnstone's approaches in oncological treatments.
Novartis
NVS
Mkt Cap237.61B
Novartis offers CAR-T cell therapy products, directly competing with Turnstone's cancer immunotherapy treatments.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is involved in various oncology treatments and has investments in gene therapy and immunotherapy, competing across multiple aspects of Turnstone's business model.

About

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Show more...
CEO
Dr. Sammy J. Farah M.B.A., Ph.D.
Employees
14
Country
US
ISIN
US90042W1009

Listings

0 Comments

Share your thoughts

FAQ

What is Turnstone Biologics stock price today?▼
The current price of TSBX is $0.36 USD — it has increased by +1.43% in the past 24 hours. Watch Turnstone Biologics stock price performance more closely on the chart.
What is Turnstone Biologics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Turnstone Biologics stocks are traded under the ticker TSBX.
Is Turnstone Biologics stock price growing?▼
TSBX stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Turnstone Biologics has showed a -5.84% decrease.
What is Turnstone Biologics revenue for the last year?▼
Turnstone Biologics revenue for the last year amounts to 0 USD.
What is Turnstone Biologics net income for the last year?▼
TSBX net income for the last year is -70.84M USD.
How many employees does Turnstone Biologics have?▼
As of April 03, 2026, the company has 14 employees.
In which sector is Turnstone Biologics located?▼
Turnstone Biologics operates in the Health Care sector.
When did Turnstone Biologics complete a stock split?▼
Turnstone Biologics has not had any recent stock splits.
Where is Turnstone Biologics headquartered?▼
Turnstone Biologics is headquartered in San Diego, US.